Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000912057-01-505832
Filing Date
2001-03-30
Accepted
2001-03-30 00:00:00
Documents
11
Period of Report
2000-12-31

Document Format Files

Seq Description Document Type Size
1 10-K a2042660z10-k.txt 10-K 204521
2 EXHIBIT 10.21 a2042660zex-10_21.txt EX-10.21 26924
3 EXHIBIT 10.22 a2042660zex-10_22.txt EX-10.22 30045
4 EXHIBIT 10.23 a2042660zex-10_23.txt EX-10.23 26944
5 EXHIBIT 10.24 a2042660zex-10_24.txt EX-10.24 30441
6 EXHIBIT 10.25 a2042660zex-10_25.txt EX-10.25 36301
7 EXHIBIT 10.26 a2042660zex-10_26.txt EX-10.26 21930
8 EXHIBIT 10.27 a2042660zex-10_27.txt EX-10.27 100427
9 EXHIBIT 10.28 a2042660zex-10_28.txt EX-10.28 2258
10 EXHIBIT 21.1 a2042660zex-21_1.txt EX-21.1 270
11 EXHIBIT 23.1 a2042660zex-23_1.txt EX-23.1 883
  Complete submission text file 0000912057-01-505832.txt   483532
Mailing Address
Business Address 216 JAFFA ROAD SHAAREI HAIR JERUSALEM ISRAEL 94383 9722534997
KERYX BIOPHARMACEUTICALS INC (Filer) CIK: 0001114220 (see all company filings)

EIN.: 134087132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-30929 | Film No.: 1587226
SIC: 8731 Services-Commercial Physical & Biological Research